Association between migraine and cognitive impairment

Lihua Gu¹,²*, Yanjuan Wang¹ and Hao Shu¹

Abstract

Background: Previous studies revealed inconsistent results regarding association between migraine and cognitive impairment. In addition, previous studies found inconsistent results regarding the association between migraine and risk of dementia. Thus, the study aimed to make a meta-analysis exploring comparison result in different types of cognitive function between migraine patients and non-migraine subjects. In addition, meta-analysis was made to explore the association between migraine and risk of dementia.

Methods: Articles published before June 2022 were searched in the following databases: PubMed, Web of Science, SCOPUS, EMBASE, EBSCO, PROQUEST, ScienceDirect and Cochrane Database of Systematic Reviews. Results were computed using STATA 12.0 software.

Results: Meta-analysis showed lower general cognitive function and language function in migraine group, compared to no migraine group (general cognitive function: standard mean difference (SMD) = −0.40, 95% CI = −0.66 to −0.15; language: SMD = −0.14, 95% confidence interval (CI) = −0.27 to −0.00), whereas the study showed no significant difference in visuospatial function, attention, executive function and memory between migraine group and no migraine group (visuospatial function: SMD = −0.23, 95% CI = −0.53 to 0.08; attention: SMD = −0.01, 95% CI = −0.10 to 0.08; executive function: SMD = −0.05, 95% CI = −0.16 to 0.05; memory: SMD = −0.14, 95% CI = −0.30 to 0.03). In addition, the meta-analysis showed a significant association between migraine and risk of dementia (odds ratio (OR)/relative risk (RR) = 1.30, 95% CI = 1.11 to 1.52).

Conclusions: In conclusion, the meta-analysis demonstrated lower general cognitive function and language function in migraine. In addition, migraine is associated with an increased risk of all-cause dementia, VaD and AD. These results suggest a significant association between migraine and cognitive impairment. Because of the association between migraine and cognitive impairment, neurological physician should be vigilant and effectively intervene in migraineurs with high risk factors of cognitive impairment to prevent the development of cognitive impairment.

Keywords: Cognition, Migraine, meta-analysis

Introduction

Migraine has been reported as the sixth most common pathogenesis of disability [1]. In addition, migraine has been reported as the second most common factor associated with disability-adjusted life years worldwide by the Global Burden of Disease study [1]. Migraine is one of the most common pain disorders and its prevalence affects up to 25% of women and 9.4% of men worldwide [2]. In addition, Pompili et al. [3] has systematically documented a strong bidirectional association between migraine and psychiatric disorders. Moreover, the relationship between migraine and psychopathology resulting in enhanced psychosocial impairment has often been clinically discussed rather than systematically studied.
These studies supported the importance of this emergent research in the field. Subjective cognitive decline is not unusual in migraine. Although cognitive impairment is identified as the core symptom of migraine, a large amount of migraine patients complain of cognitive impairment, especially deficits in attention and memory. However, previous studies revealed inconsistent results regarding association between migraine and cognitive impairment. Indeed, some studies reported that migraine is associated with a lower cognitive function during both interictal [7] or ictal [8, 9] periods. Wen et al. reported that migraine patients tend to score higher in cognition tests than non-migraine subjects [10]. Conversely, some studies did not show any difference in cognitive function between migraine patients and non-migraine subjects [11–13]. In addition, previous studies found inconsistent results regarding the association between migraine and risk of dementia [14–16]. We hypothesized that migraine patients showed lower general cognitive function, language, visuospatial function, attention, executive function and memory, compared to no migraine group. Additionally, we hypothesized that migraine was significantly associated with risk of dementia. The study aimed to make a meta-analysis exploring comparison result in different types of cognitive function between migraine patients and non-migraine subjects. In addition, meta-analysis was made to explore the association between migraine and risk of dementia.

Methods
The study was made according to the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) guideline [17]. The PRISMA Checklist is included in the Table 1.

Search strategy
We searched for articles published before June 2022 in the following databases: PubMed, Web of Science, SCOPUS, EMBASE, EBSCO, PROQUEST, Science-Direct and Cochrane Database of Systematic Reviews. Included studies explored association between migraine and cognitive impairment. We used the following search terms: (“migraine” OR “hemicrania” OR “cephalalgia”) AND (“cognitive impairment” OR “cognitive deficit” OR “dementia” OR “Alzheimer’s disease”).

Inclusion and exclusion criteria
We included studies investigating the association between migraine and cognitive impairment. We excluded studies according to the following exclusion criteria: 1) Studies which did not provide sufficient information regarding cognitive function in both migraine and healthy controls (HCs); 2) Studies which did not provide sufficient information for odds ratios (ORs) in case-control studies or relative risks (RRs) in cohort studies and their 95% confidence intervals (CIs); 3) Meta-analyses, reviews and case-reports.

Data extraction
We extracted the following data from finally included studies: Author, publication year, study type, type of migraine, study location, sample size, mean age of patients, gender of patients, disease duration of migraine, attack frequency of migraine, duration of migraine attack, pain intensity, explored cognitive functions, adjusted variables, follow-up time and results.

Cognitive tests included
According to previous studies [18], neuropsychological examinations were divided into 6 cognitive domains: (1) general cognitive function, (2) language, (3) visuospatial function, (4) attention function, (5) executive function, (6) memory function. General cognitive function was evaluated by the Mini-mental state examination (MMSE) and Montreal cognitive assessment (MoCA). Language function was assessed by Fluency test (phonemic fluency test and verbal fluency test) and Mill hill vocabulary test part A. Visuospatial function was assessed by Rey-Osterrieth complex figure test (ROCF) and Clock drawing test (CDT). Attention function was evaluated by Trail making test (TMT)-A, Digital Symbol Substitution Test (DSST), Letter digit substitution test (LDST) and Stroop color and word test (SCWT) A, B. Executive function was assessed by Digital span test (DST)-backward, TMT-B, SCWT C and Semantic similarity test. We identified and recorded the mean value and standard deviation (SD) of raw scores of each neuropsychological test. Higher raw scores indicate better cognitive function on almost all the cognitive tests. However, the TMT (A and B) and SCWT (A, B and C) present an exception, as there is a reversed interpretation for the raw scores (where longer time indicates poorer performance). For this reason, the TMT (A and B) and SCWT (A, B and C) scores of the study have been reversed, so that higher scores indicate better performance. The mean value and SD of cognitive scores in migraine and no migraine groups were standardized and reported in relation to the mean value in no migraine groups. Then, each cognitive domain’s standardized score was determined by averaging the standardized scores of relevant tests. Risk of dementia was measured by calculating the incidences of dementia.

Meta-analysis
We used STATA 12.0 software to compute results. Standardized mean values and SD of cognitive function
| Section/topic                  | # | Checklist item                                                                 | Reported on page # |
|-------------------------------|---|----------------------------------------------------------------------------------|-------------------|
| TITLE                         |   | Identify the report as a systematic review, meta-analysis, or both.              | 1                 |
| ABSTRACT                      |   | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | 1, 2              |
| INTRODUCTION                  |   | Rationale. Describe the rationale for the review in the context of what is already known. | 2                 |
|                              |   | Objectives. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). | 2, 3              |
| METHODS                       |   | Protocol and registration. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. | 3                 |
|                              |   | Eligibility criteria. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. | 3                 |
|                              |   | Information sources. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | 3                 |
|                              |   | Search. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | 3                 |
|                              |   | Study selection. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). | 3                 |
|                              |   | Data collection process. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | 3                 |
|                              |   | Data items. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. | 3                 |
|                              |   | Risk of bias in individual studies. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | 4                 |
|                              |   | Summary measures. State the principal summary measures (e.g., risk ratio, difference in means). | 4                 |
|                              |   | Synthesis of results. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis. | 4                 |
|                              |   | Risk of bias across studies. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). | 4                 |
|                              |   | Additional analyses. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. | 4                 |
| RESULTS                       |   | Study selection. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. | 4                 |
|                              |   | Study characteristics. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. | 4, 5              |
|                              |   | Risk of bias within studies. Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). | 5–7               |
|                              |   | Results of individual studies. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. | 5–7               |
|                              |   | Synthesis of results. Present results of each meta-analysis done, including confidence intervals and measures of consistency. | 5–7               |
|                              |   | Risk of bias across studies. Present results of any assessment of risk of bias across studies (see item 15). | 5–7               |
|                              |   | Additional analysis. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression) [see item 16]). | 5–7               |
| DISCUSSION                    |   | Summary of evidence. Summarize the main findings, including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). | 8                 |
|                              |   | Limitations. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). | 9                 |
|                              |   | Conclusions. Provide a general interpretation of the results in the context of other evidence, and implications for future research. | 9, 10             |
| FUNDING                       |   | Funding. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. | 10                |

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:https://doi.org/10.1371/journal.pmed1000097
For more information, visit: www.prisma-statement.org
### Table 2: Characteristics of studies regarding comparison in various cognition between migraine group and no migraine group

| Study                  | Study type | Type of migraine | Study location | Sample size | Age (years) | Gender (male%) | Disease duration (years) | Attack frequency (times/year) | Duration of migraine attack (%) | Pain intensity (0–10) | Cognitive function                                      |
|------------------------|------------|------------------|----------------|-------------|-------------|----------------|--------------------------|------------------------------|-------------------------------|-------------------|----------------------------------------------------------|
| Zeitlin et al. 1984 [19]| Cross-sectional | migraine         | UK             | 19/19       | 36.3        | NR             | NR                       | NR                           | NR                           | NR              | Attention, executive function                             |
| Jelicic et al. 2000 [12]| Cross-sectional | migraine         | The Netherlands | 99/1753     | 52.0        | 35%            | NR                       | NR                           | NR                           | NR              | Attention, memory                                        |
| Calandre et al. 2002 [20]| Cross-sectional | migraine         | Spain          | 60/30       | 37.8        | 36.7%          | NR                       | NR                           | NR                           | NR              | Executive function, attention, memory                   |
| Haverkamp et al. 2002 [21]| Cross-sectional | migraine         | Germany        | 37/17       | 10          | 59.4%          | NR                       | NR                           | NR                           | NR              | Memory                                                   |
| Gaist et al. 2005 [11]  | Cohort     | MWoA and MwA    | Denmark        | 536/857     | 56.4 (6.2)  | 29.8%          | NR                       | NR                           | NR                           | NR              | Executive function, attention, memory                   |
| Pearson et al. 2006 [13]| Cross-sectional | MWoA and MwA    | UK             | 74/74       | 64.4        | 26%            | NR                       | NR                           | NR                           | NR              | Executive function, language, memory                     |
| Camarda et al. 2007 [7] | Cross-sectional | MwA              | Italy          | 45/90       | 33.6 (8.6)  | 31.1%          | 13.3 (7.7)               | 34.4 (20.3)                  | 296 (209)                    | 2.0 (0.8) | General cognitive function, executive function, language, attention |
| Kalaydjian et al. 2007 [22] | Cross-sectional | Migraine (MwA) | USA            | 204/1244    | 47.5 (12.5) | 14.7%          | NR                       | NR                           | NR                           | NR              | General cognitive function                              |
| Baars et al. 2010 [23]  | Cohort     | migraine         | the Netherlands | 99/1724     | 47.1 (12.9) | 36.4%          | NR                       | NR                           | NR                           | NR              | General cognitive function                              |
| Rist et al. 2011 [24]   | Cross-sectional | migraine         | France         | 167/938     | 69.0 (29)   | 15.0%          | NR                       | NR                           | NR                           | NR              | General cognitive function, executive function, memory   |
| Martins et al. 2012 [25] | Cross-sectional | migraine         | Portugal       | 61/367      | 619         | 8.19%          | NR                       | NR                           | NR                           | NR              | language, executive function                             |
| Rist et al. 2012 [26]   | Cohort     | MWoA and MwA    | USA            | MWoA 248/ MwA 195/ HC 5496 | MWoA 65.3 (3.6)/ MwA 65.9 (3.9) | NR | NR | NR | NR | language, executive function |
| Study                  | Study type                  | Type of migraine | Study location | Sample size | Age (years) | Gender (male%) | Disease duration (years) | Attack frequency (times/year) | Duration of migraine attack (h) | Pain intensity (0–10) | Cognitive function                                                                 |
|-----------------------|-----------------------------|------------------|----------------|-------------|-------------|-----------------|--------------------------|------------------------------|------------------------------|------------------------|----------------------------------------------------------------------------------|
| Santangelo et al. 2016 [27] | Cross-sectional            | MWoA             | Italy          | 72/72       | 34.9±11.2   | 12.5%           | 15.1 ± 11.6             | 73.2                         | NR                           | NR                     | General cognitive function, executive function, language, attention, memory       |
| Wang et al. 2016 [28]  | Cross-sectional             | migraine         | China          | MV 40/ Simple migraine 40/40 | 42.7 ± 13.3/ Simple migraine 42.2 ± 15.4 | MV 40%/ Simple migraine 45% | NR                        | NR                           | NR                           | NR                     | General cognitive function, executive function, language, attention, memory       |
| Wen et al. 2016 [10]   | Cross-sectional             | migraine         | The Nether-lands | 1021/5399   | 63.8 (11.1) | 18.7%           | NR                      | NR                           | NR                           | NR                     | General cognitive function                                                                 |
| Huang et al. 2017 [29] | Cross-sectional             | migraine         | China          | 34/24       | 36.0±10.065 | NR              | 11.25 ± 9.290          | 42.384                        | 234 ± 24.197                 | 6.383 ± 1.670          | General cognitive function, executive function, attention, memory, language, visuospatial function |
| Lo et al. 2017 [30]    | Cross-sectional             | MWoA and MwA     | Italy          | 14/14/14    | MwA 41.28 ±13.44 | MwA 40.75 ±11.82 | NR                       | MwA 10.9 ± 3.7               | MwA 60.6                    | NR                     | Attention, language, memory, executive functions                                 |
| Ferreira et al. 2018 [31] | Cross-sectional            | CM               | Brazil         | 30/30       | 33.7        | 4.3%            | NR                      | 144                          | NR                           | 8.5                    | General cognitive function, executive function, attention, memory, language, visuospatial function |
| Tunç et al. 2018 [32]  | Cross-sectional             | migraine         | Turkey         | 100/80      | 36.7 ± 9.4  | 9%              | 7.4 ± 7.1               | 43.2                         | NR                           | NR                     | General cognitive function, attention, memory, language, visuospatial function |
| Study                  | Study type | Type of migraine | Study location | Sample size | Age (years) | Gender (male%) | Disease duration (years) | Attack frequency (times/year) | Duration of migraine attack (h) | Pain intensity (0–10) | Cognitive function                  |
|------------------------|------------|------------------|----------------|-------------|-------------|----------------|-------------------------|-------------------------------|-------------------------------|------------------------|------------------------------------|
| Baschi et al. 2019 [33]| Cross-sectional | MWoA             | Italy          | 21/21       | 29 (4.32)   | 42.8%          | 8.57 (3.69)             | NR                           | NR                           | NR                     | Visuospatial memory, Verbal memory, Attention, Executive functions |
| Karami et al. 2019 [34]| Cross-sectional | migraine         | Iran           | 30/31       | 25.33       | NR             | NR                     | NR                           | NR                           | NR                     | Memory                               |
| Martins et al. 2020 [35]| Cohort     | migraine         | Portugal       | 35/214      | 61.1 ± 7.4  | 6%             | NR                     | NR                           | NR                           | NR                     | General cognitive function, executive function, memory |

Abbreviations: CM chronic migraine, MWoA migraine with aura, MWoA migraine without aura, NR not reported, PIQ performance intelligent quotient, TIQ total intelligence quotient, UK United Kingdom, USA United States, VIQ verbal intelligence quotient
Table 3  Characteristics of studies regarding association between migraine and risk of dementia

| Study                | Study type | Type of migraine | Study location | Sample size | Age (years) | Gender (male%) | Adjusted variables                                                                 | Follow-up time (years) | Result                                      |
|----------------------|------------|------------------|----------------|-------------|-------------|---------------|-------------------------------------------------------------------------------------|------------------------|---------------------------------------------|
| Tyas et al. 2001 [36]| case-control| migraine         | USA            | AD 36/HC 658| 79.8 ± 5.7  | 33.3%         | age, education and sex, occupational exposure to fungicides/defoliants               | NA                     | AD 3.49 (1.39–8.77)                         |
| Chuang et al. 2013   | cohort     | Migraine         | China          | Migraine 33,468, no Migraine 133,872 | 42.4        | 28.7%         | age, sex, diabetes, hypertension, depression, head injury, and CHD                   | 12                     | All-cause Dementia 1.33 (1.22–1.46)         |
| Pavlovic et al. 2013 | cohort     | Migraine         | USA            | Migraine 136 no Migraine 838 | ≥ 70        | NA            | age, sex, education, depression, hypertension, diabetes, stroke, myocardial infarction, and other heart conditions | NA                     | All-cause dementia 0.56 (0.27–1.18)         |
| Hagen et al. 2014 [39]| cohort     | Migraine (MwA, MWoA) | Norway         | Migraine 6740, no headache 29,988 | 49.7        | 46.1%         | age, sex, education, total HADS score, and smoking                                  | 6                      | VaD 2.9 (1.3–6.6) MwA 3.0 (0.4–22.5) MWoA 2.7 (1.1–6.7) |
| Tzeng et al. 2017   | cohort     | Migraine         | China          | Migraine 1922 no headache 10,860 | ≥ 20        | 31.96         | urbanization level, insured premium                                                  | 10                     | All-cause Dementia 1.95 (1.57–2.33)         |
| Kostev et al. 2019[41]| cohort     | Migraine         | Germany        | Migraine 3727, no Migraine 3727 | 67.7        | 27.1%         | age, sex, index year, and co-diagnoses using a propensity score method               | 10                     | All-cause dementia 1.43 (1.07–1.78) VaD 1.51 (0.74–2.28) AD 1.87 (1.21–2.52) Unspecified dementia 1.11 (0.57–1.65) |
| Lee et al. 2019[14] | case-control| Migraine         | Seoul          | Dementia 11,438 HC 45,752 | ≥ 60        | 32%           | age, sex, income, region of residence, hypertension, diabetes, and dyslipidemia     | NA                     | All-cause dementia 1.13 (1.05–1.23)         |
| Morton et al. 2019   | cohort     | Migraine         | Canada         | Migraine 200 no Migraine 479 | 75.9        | 38.1%         | age, sex, education, depression, hypertension, diabetes, stroke, myocardial infarction, and other heart conditions | 5                      | 297 (125–661) AD 422 (1.59–10.42) VaD 1.52 (2.20–7.23) |
| Study                     | Study type | Type of migraine | Study location | Sample size | Age (years) | Gender (male%) | Adjusted variables                                                                 | Follow-up time (years) | Result                                      |
|--------------------------|------------|------------------|----------------|-------------|-------------|---------------|-------------------------------------------------------------------------------------|------------------------|---------------------------------------------|
| George et al. 2020       | cohort     | Migraine (MwA, MWoA) | USA            | Migraine 1397 no Migraine 9955 | 60          | 44.1%         | age, race-center, APOE ε4, income and education, BMI, smoking status, hypertension, diabetes, prevalent CHD, drinking status, HDL cholesterol, and total cholesterol | 21                     | All-cause Dementia 1.04 (0.91–1.2) MwA 1.12 (0.88, 1.43) MWoA 1.01 (0.86, 1.19) |
| Islamoska et al. 2020    | Case-control | Migraine (MwA, MWoA) | Denmark        | Migraine 1397 no Migraine 9955 | 18.3        | 51%           | sex, country of origin, marital status, educational level, headache diagnoses, psychiatric morbidities, and Charlson Comorbidity Index | 18.3                   | All-cause Dementia 1.5 (1.28–1.76) MwA 2.11 (1.48–3.00) MWoA 1.19 (0.84–1.70) All other migraine types 1.48 (1.23–1.78) |
| Liang et al. 2022        | cohort     | Migraine         | Sweden         | Migraine 352 no Migraine 305 | NR          | NR            | NR                                                                   | 3 or 6                 | All-cause Dementia 0.49 (0.20–1.21) MWoA 0.66 (0.26–1.66) |

*Abbreviations: AD, Alzheimer's disease, APOE apolipoprotein E, CHD coronary heart disease, HADS Hospital Anxiety and Depression Scale, HC healthy control, MwA migraine with aura, MWoA migraine without aura, NA not applicable, NR not reported, USA United States, VaD vascular dementia*
associated scores were computed. In addition, ORs/RRs and their CIs were computed. We used Q test and $I^2$ to evaluate heterogeneities between included studies. We used random effects models to compute results. We used subgroup studies (for different ethnicities and study types) to explore the source of the heterogeneity. We used meta-regression analysis to investigate the source of heterogeneity. We used sensitivity analysis to assess the study stabilization. We used Begg’s test, Egger’s test and funnel plot to assess publication bias.

**Results**

**Study characteristics**

Supplementary Fig. 1 showed the inclusion and exclusion process. Tables 2 and 3 showed study characteristics. $N = 22$ studies [7, 10–13, 19–35] (including 3295 migraine patients) investigated cognitive function in both migraine and HCs. These studies included $N = 4$ cohort studies and $N = 18$ cross-sectional studies. $N = 11$ studies [14–16, 36–43] included $N = 3$ case-control studies [14, 16, 36] (including 12,871 dementia patients and 56,365 no dementia participants) and $N = 8$ cohort studies [15, 37–43] (including 47,942 migraine patients and 190,024 HCs) investigated the association between migraine and risk of dementia.

**meta-analysis results**

**Comparison in general cognitive function**

Meta-analysis showed a lower general cognitive function in migraine group, compared to no migraine group with a random effects model (standard mean difference (SMD) = −0.40, 95% CI = −0.66 to −0.15, $I^2 = 92.8\%$, $p < 0.001$, Fig. 1). Subgroup analysis showed no significant difference in general cognitive function between migraine group and no migraine group in Caucasian, whereas migraine group showed a lower general cognitive function in migraine group, compared to no migraine group in Asian (Supplementary Table 1 and Supplementary Fig. 2. A). Subgroup analysis showed a lower general cognitive function in migraine group, compared to no migraine group in cross-sectional studies (Supplementary Table 2 and Supplementary Fig. 2. B). Meta-regression analysis showed that age of migraine, gender of migraine, disease duration of migraine, attack frequency...
of migraine and pain intensity were not responsible for the heterogeneity across studies (Supplementary Table 3). Sensitivity analysis indicated no changes in the direction of effect when anyone study was excluded (Supplementary Fig. 3. A). Begg’s test, Egger’s tests and funnel plots indicated a significant risk of publication bias (Supplementary Table 4 and Supplementary Fig. 3. B).

**Comparison in language function**

Meta-analysis showed a lower language function in migraine group, compared to no migraine group with a random effects model (SMD = −0.14, 95% CI = −0.27 to −0.00, I² = 65.1%, p = 0.001, Fig. 2). Subgroup analysis showed no significant difference in language function between migraine group and no migraine group in Caucasian (Supplementary Table 1 and Supplementary Fig. 4. A). Subgroup analysis showed a lower language function in migraine group, compared to no migraine group in cross-sectional studies (Supplementary Table 2 and Supplementary Fig. 4. B). Meta-regression analysis showed that age of migraine was responsible for the heterogeneity across studies, whereas gender of migraine, disease duration of migraine, attack frequency of migraine, duration of migraine attack and pain intensity were not responsible for the heterogeneity across studies (Supplementary Table 3). Sensitivity analysis indicated no changes in the direction of effect when anyone study was excluded (Supplementary Fig. 5. A). Begg’s test, Egger’s tests and funnel plots indicated no significant risk of publication bias (Supplementary Table 4 and Supplementary Fig. 5. B).

**Comparison in visuospatial function**

In addition, meta-analysis showed no significant difference in visuospatial function between migraine group and no migraine group with a random effects model (SMD = −0.23, 95% CI = −0.53 to 0.08, I² = 56.1%, p = 0.077, Fig. 3). Subgroup analysis showed a lower visuospatial function in migraine group, compared to no migraine group in Caucasian (Supplementary Table 1 and Supplementary Fig. 6). Meta-regression analysis showed that age of migraine, gender of migraine, disease duration of migraine and attack frequency of migraine...
were not responsible for the heterogeneity across studies (Supplementary Table 3).

**Comparison in attention function**

However, no significant difference in attention between migraine group and no migraine group was observed (SMD = −0.01, 95% CI = −0.10 to 0.08, I² = 52.6%, p = 0.002, Fig. 4). Subgroup analysis showed no significant difference in attention between migraine group and no migraine group in Caucasian (Supplementary Table 1 and Supplementary Fig. 7. A). Subgroup analysis showed no significant difference in attention between migraine group and no migraine group in cross-sectional studies (Supplementary Table 1 and Supplementary Fig. 7. B). Meta-regression analysis showed that age of migraine and gender of migraine were responsible for the heterogeneity across studies, whereas attack frequency of migraine, duration of migraine attack and pain intensity were not responsible for the heterogeneity across studies (Supplementary Table 3). Sensitivity analysis indicated no changes in the direction of effect when any study was excluded (Supplementary Fig. 8. A). Begg’s test, Egger’s test and funnel plots indicated no significant risk of publication bias (Supplementary Table 4 and Supplementary Fig. 8. B).

**Comparison in executive function**

Meta-analysis showed no significant difference in executive function between migraine group and no migraine group with random effects models (SMD = −0.05, 95% CI = −0.16 to 0.05, I² = 54.7%, p = 0.001, Fig. 5). Subgroup analysis showed no significant difference in executive function between migraine group and no migraine group in Caucasian (Supplementary Table 1 and Supplementary Fig. 9. A). Subgroup analysis showed no significant difference in executive function between migraine group and no migraine group in cross-sectional and cohort studies (Supplementary Table 1 and Supplementary Fig. 9. B). Meta-regression analysis showed that gender of migraine was responsible for the heterogeneity across studies, whereas age of migraine, attack frequency of migraine, attack frequency of migraine, and pain intensity were not responsible for the heterogeneity across studies (Supplementary Table 3). Sensitivity analysis indicated no changes in the direction of effect when any study was excluded (Supplementary Fig. 10. A). Begg’s test, Egger’s test and funnel plots indicated no significant risk of publication bias (Supplementary Table 4 and Supplementary Fig. 10. B).
Comparison in memory function

Meta-analysis showed no significant difference in memory between migraine group and no migraine group with random effects models (SMD = −0.14, 95% CI = −0.30 to 0.03, I² = 82.5%, p < 0.001, Fig. 6). Subgroup analysis showed no significant difference in memory between migraine group and no migraine group in Caucasian, whereas migraine group showed a lower memory function, compared to no migraine group in Asian (Supplementary Table 1 and Supplementary Fig. 11. A). Subgroup analysis showed no significant difference in memory between migraine group and no migraine group in cross-sectional studies (Supplementary Table 1 and Supplementary Fig. 11. B). Meta-regression analysis showed that age of migraine, gender of migraine, disease duration of migraine, attack frequency of migraine and duration of migraine were not responsible for the heterogeneity across studies (Supplementary Table 3). Sensitivity analysis indicated no changes in the direction of effect when anyone study was excluded (Supplementary Fig. 12. A). Begg’s test, Egger’s tests and funnel plots indicated no significant risk of publication bias (Supplementary Table 4 and Supplementary Fig. 12. B).

Association between migraine and risk of dementia

The meta-analysis showed a significant association between migraine and risk of dementia with a random effects model (OR/RR = 1.30, 95% CI = 1.11 to 1.52, I² = 83.5%, p < 0.001, Fig. 7). Subgroup analysis showed no significant association between migraine and risk of dementia in Caucasian, whereas a significant association between migraine and risk of dementia was showed in Asian (Supplementary Table 1 and Supplementary Fig. 13. A). Subgroup analysis showed a significant
association between migraine and risk of dementia in cohort studies (Supplementary Table 1 and Supplementary Fig. 13. B). Meta-regression analysis showed that age of migraine and gender of migraine were not responsible for the heterogeneity across studies (Supplementary Table 3).

However, the study showed no significant association between migraine without aura (MWoA) and risk of dementia with a random effects model (OR/RR = 1.03, 95% CI 0.89 to 1.19, I² = 0.0%, p = 0.453, Supplementary Fig. 14. A). In addition, the study showed significant associations between migraine and risk of vascular dementia (VaD), Alzheimer’s disease (AD) with random effects models (VaD: OR/RR = 1.84, 95% CI 1.18 to 2.88, I² = 0.0%, p = 0.423, Supplementary Fig. 14. B; AD: OR/RR = 2.60, 95% CI 1.51 to 4.48, I² = 43.8%, p = 0.169, Supplementary Fig. 14. C).

### Discussion

Meta-analysis showed lower general cognitive function and language function in migraine group, compared to no migraine group, whereas the study showed no significant difference in visuospatial function, attention, executive function and memory between migraine group and no migraine group. In addition, the meta-analysis showed a significant association between migraine and risk of dementia.

The present study compared various types of cognition between migraine group and no migraine group. Included studies showed contradictory results on association between migraine and cognitive impairment. Cross-sectional and cohort studies reported worse cognitive function in migraine patients [25] or no association [11–13, 23, 26], whereas some longitudinal studies
showed reduced decline of the general cognitive function and executive function in migraine [22, 24]. In addition, Wen et al. [10] reported that migraineurs, particularly migraineurs with aura, tend to score higher in cognition tests than non-migraineurs. These inconsistencies might be caused by different methodological issues including different migraine assessment methods. In addition, clinical features (age, gender, types of migraine, disease duration of migraine, attack frequency of migraine, duration of migraine attack, pain intensity, follow-up duration, headache medication use, diet, sleep, or physical activity, et al.) might be the source of inconsistencies. The effect of age and gender on association between migraine and cognitive impairment has been verified by meta-regression in the present study. More large-scale cohort studies were essential to explore the association between migraine and cognitive impairment.

Up to now, the exact mechanism regarding association between migraine and cognitive impairment is still not fully understood. Recent studies provided information for alterations in brain functional reorganization of cognitive cerebral networks in migraine. These cognitive cerebral networks included default mode network (DMN) [44], executive control network (ECN) [45], visual network [46], et al. The DMN plays an important role in several cognitive processes, such as memory, problem solving and planning [47]. The ECN mainly includes the dorsolateral prefrontal cortex (DLPFC) and the posterior parietal cortex (PPC) [48]. The frontal lobe involves in

![Forest plots regarding comparison in memory between migraine group and no migraine group. Abbreviations: CI, confidence interval; SMD, standard mean difference](image-url)
regulating behavior, complex planning, and learning [49]. Visual processing speed is linked to functional connectivity between right frontoparietal and visual networks [50]. In addition, somatic pain can drive a person to focus on the pain and shift his attention from other cognitive tasks. These mechanisms might contribute to the association between migraine and cognitive impairment.

The meta-analysis showed a significant association between migraine and risk of dementia. The result is corresponding to a recent meta-analysis (including \( N=9 \) observational studies) which demonstrated that migraine may be a risk factor for dementia, particularly VaD and AD [51]. Previous studies supported that some vascular risk factors of VaD (including hypertension, diabetes and stroke) could cause migraine [52, 53]. In addition, migraine showed more prevalent in white matter hyper-intensities (WMH), which shows an increased risk of dementia both VaD and AD [54, 55], compared to HCs. However, only \( N=3 \) studies explored the association between migraine and risk of VaD or AD. Thus, more studies were essential to explore the association between migraine and risk of VaD or AD.

The present meta-analysis showed high heterogeneity between studies investigating association between migraine and risk of dementia. The present study mainly included observational studies, which were both clinically and methodologically inhomogeneous. Thus, high heterogeneity is inevitable and not surprising. Subgroup analysis showed no significant association between migraine and risk of dementia in Caucasian, whereas a significant association between migraine and risk of dementia was showed in Asian. Different ethnicities might be the source of heterogeneity. In addition, other clinical features, such as age, gender, types of migraine, disease duration of migraine, attack frequency of migraine, duration of migraine attack, pain intensity and follow-up duration, might be also the source of heterogeneity. In the present study, we selected studies according to explicit inclusion and exclusion criteria to decrease heterogeneity. However, heterogeneity still exists.

There are some limitations in the study. Firstly, the heterogeneity across studies is unavoidable. The high heterogeneity might have an impact on the reliability of our
results. The high heterogeneity might be caused by different methodological issues and clinical features. More large-scale cohort studies were essential to explore the association between migraine and cognitive impairment. Secondly, the study included limited number of studies exploring the association between migraine and risk of VaD or AD. More studies were essential to explore the association between migraine and risk of VaD or AD. Thirdly, some included studies were case-control designed, which might cause recall bias. The recall of migraine may be uncertain and may result in a wrong diagnosis of migraine.

Conclusion
In conclusion, the meta-analysis demonstrated lower general cognitive function and language function in migraine. In addition, migraine is associated with an increased risk of all-cause dementia, VaD and AD. These results suggest a significant association between migraine and cognitive impairment. Because of the association between migraine and cognitive impairment, neurological physician should be vigilant and effectively intervene in migraineurs with high risk factors of cognitive impairment to prevent the development of cognitive impairment.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s10194-022-01462-4.

Additional file 1: Figure S1. Flow of information through the different stages of a meta-analysis.

Additional file 2: Table S1. Results of subgroup analysis in different ethnicities.

Additional file 3: Figure S2. Subgroup analysis regarding comparison in general cognitive function between migraine group and no migraine group in different ethnicities (A) and study types (B). Abbreviations: CI, confidence interval; SMD, standard mean difference.

Additional file 4: Table S2. Results of subgroup analysis in different study types.

Additional file 5: Table S3. Results of meta-regression analysis.

Additional file 6: Figure S3. Sensitivity analysis (A) and funnel plot (B) regarding comparison in general cognitive function between migraine group and no migraine group.

Additional file 7: Figure S4. Subgroup analysis regarding comparison in language between migraine group and no migraine group in different ethnicities (A) and study types (B). Abbreviations: CI, confidence interval; SMD, standard mean difference.

Additional file 8: Table S4. Results of publication bias.

Additional file 9: Figure S5. Sensitivity analysis (A) and funnel plot (B) regarding comparison in language between migraine group and no migraine group.

Additional file 10: Figure S6. Subgroup analysis regarding comparison in visuospatial function between migraine group and no migraine group in different ethnicities. Abbreviations: CI, confidence interval; SMD, standard mean difference.

Additional file 11: Figure S7. Subgroup analysis regarding comparison in attention between migraine group and no migraine group in different ethnicities (A) and study types (B). Abbreviations: CI, confidence interval; SMD, standard mean difference.

Additional file 12: Figure S8. Sensitivity analysis (A) and funnel plot (B) regarding comparison in attention between migraine group and no migraine group.

Additional file 13: Figure S9. Subgroup analysis regarding comparison in executive function between migraine group and no migraine group in different ethnicities (A) and study types (B). Abbreviations: CI, confidence interval; SMD, standard mean difference.

Additional file 14: Figure S10. Sensitivity analysis (A) and funnel plot (B) regarding comparison in executive function between migraine group and no migraine group.

Additional file 15: Figure S11. Subgroup analysis regarding comparison in memory between migraine group and no migraine group in different ethnicities (A) and study types (B). Abbreviations: CI, confidence interval; SMD, standard mean difference.

Additional file 16: Figure S12. Sensitivity analysis (A) and funnel plot (B) regarding comparison in memory between migraine group and no migraine group.

Additional file 17: Figure S13. Subgroup analysis regarding association between migraine and risk of dementia in different ethnicities. Abbreviations: CI, confidence interval; OR, odds ratio; RR, relative risk.

Additional file 18: Figure S14. Forest plots regarding association between MWoA and risk of dementia, migraine and risk of VaD, migraine and risk of AD. Abbreviations: AD, Alzheimer’s disease; CI, confidence interval; MWoA, migraine without aura; OR, odds ratio; RR, relative risk; VaD, vascular dementia.

Authors’ contributions
Lihua Gu carried out study design, supervision, data collection, manuscript writing and manuscript revision. Yanjuan Wang participated in the data collection, data analysis and manuscript writing. Hao Shu participated in data analysis and software use. All authors read and approved the final manuscript.

Funding
This study was supported by the National Natural Science Foundation of China (No. 81901108).

Declarations
Competing interests
No conflict of interest.

Author details
1Department of Neurology, Affiliated ZhongDa Hospital, School of Medicine, Southeast University, No. 87 Dingjiaqiao Road, Nanjing 210009, Jiangsu, China.
2Department of Neurology, Tianjin Huanhu Hospital, Tianjin, China.

Received: 6 June 2022 Accepted: 16 July 2022 Published: 26 July 2022

References
1. GBD 2015 Neurological Disorders Collaborator Group (2015) Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the global burden of disease study [J]. Lancet Neurol 2015: a systematic analysis for the global burden of disease study [J]. Lancet Neurol 2017 16:877-97
2. Roncaltato M, Fabbri L, Recchia G et al (2000) An epidemiological study to assess migraine prevalence in a sample of Italian population presenting to their GPs [J]. Eur Neurol 43(2):102–106
3. Pompili M, Serafini G, Di Cosimo D et al (2010) Psychiatric comorbidity and suicide risk in patients with chronic migraine [J]. Neuropsychiatr Dis Treat 6:81–91
4. D’aiuto C, Gamm S, Grenier S et al (2022) The association between chronic pain conditions and subclinical and clinical anxiety among community-dwelling older adults Consulting in Primary Care [J]. Pain Med (Malden, Mass) 23(6):1118–1126
5. Sucksdorf D, Brown AS, Chudal R et al (2016) Parental and comorbid migraine in individuals with bipolar disorder: a nationwide register study [J]. J Affect Disord 206:109–114
6. Dindo LN, Recober A, Haddad R et al (2017) Comorbidity of migraine, major depressive disorder, and generalized anxiety disorder in adolescents and young adults [J]. Int J Behav Med 24(4):528–534
7. Camarda C, Monastero R, Pipia C et al (2007) Interictal executive dysfunction in migraineurs without aura: relationship with duration and intensity of attacks [J]. Cephalalgia 27(10):1094–1100
8. Gil-Gouveia R, Oliveira AG, Martins IP (2015) Cognitive dysfunction during migraine attacks: a study on migraine without aura [J]. Cephalalgia 35(8):662–674
9. Gil-Gouveia R, Oliveira AG, Martins IP (2016) The impact of cognitive symptoms on migraine attack-related disability [J]. Cephalalgia 36(5):422–430
10. Wen K, Nguyen NT, Hofman A et al (2016) Migraine is associated with better cognition in the middle-aged and elderly: the Rotterdam study [J]. Eur J Neurol 23(10):1510–1516
11. Gaist D, Pedersen L, Madsen C et al (2005) Long-term effects of migraine on cognitive function: a population-based study of Danish twins [J]. Neurology 64(6):600–607
12. Jelicic M, Van Boxtel MP, Houx PJ et al (2000) Does migraine headache affect cognitive function in the elderly? Report from the Maastricht aging study (MAAS) [J]. Headache 40(9):715–719
13. Pearson AJ, Chronicle EP, Maylor EA et al (2006) Cognitive function is not impaired in people with a long history of migraine: a blinded study [J]. Cephalalgia 26(1):74–80
14. Lee SY, Lim JS, Oh DJ et al (2019) Increased risk of neurodegenerative dementia in women with migraines: a nested case-control study using a national sample cohort [J]. Medicine 98(7):e14467
15. George KM, Folsom AR, Sharrett AR et al (2020) Migraine headache and risk of dementia in the atherosclerosis risk in communities neurocognitive study [J]. Headache 60(5):946–953
16. Islamoska S, Hansen AM, Wang HX et al (2020) Mid- to late-life migraine diagnoses and risk of dementia: a national register-based follow-up study [J]. J Headache Pain 21(1):98
17. Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement [J]. BMJ 339:b2535
18. Lezak MD (1995) Neuropsychological assessment (3rd ed.) [J]. J Neurol Neurosurg Psychiatry 58(6):655–664
19. Zethin C, Oddý M (1984) Cognitive impairment in patients with severe migraine [J]. Br J Clin Psychol 23(1):27–35
20. Calandre EP, Bembibre J, Arnedo ML et al (2002) Cognitive disturbances and regional cerebral blood flow abnormalities in migraine patients: their relationship with the clinical manifestations of the illness [J]. Cephalalgia 22(4):291–297
21. Haverkamp F, H NSCHEID A, M LLER-SINIK K (2002) Cognitive development in children with migraine and their healthy unaffected siblings [J]. Headache 42(8):776–779
22. Kalaydjian A, Zandi PR, Swartz KL et al (2007) How migraines impact cognitive function: findings from the Baltimore ECA [J]. Neurology 68(17):1417–1424
23. Baars MA, Van Boxtel MP, Jolles J (2010) Migraine does not affect cognitive decline: results from the Maastricht aging study [J]. Headache 50(2):176–184
24. Rist PM, Dufohl C, Gilmour MM et al (2011) Migraine and cognitive decline in the population-based EVA study [J]. Cephalalgia 31(12):1291–1300
25. Martins IP, Gil-Gouveia R, Silva C et al (2012) Migraine, headaches, and cognition [J]. Headache 52(10):1471–1482
26. Rist PM, Kang JH, Buring J et al (2012) Migraine and cognitive decline among women: prospective cohort study [J]. BMJ 345:e5027
27. Santangelo G, Russo A, Troiano L et al (2016) Cognitive dysfunctions and psychological symptoms in migraine without aura: a cross-sectional study [J]. J Headache Pain 17(1):76
28. Wang N, Huang HL, Zhou H et al (2016) Cognitive impairment and quality of life in patients with migraine-associated vertigo [J]. Eur Rev Med Pharmacol Sci 20(23):4913–4917
29. Huang L, Juan Dong H, Wang X et al (2017) Duration and frequency of migraines affect cognitive function: evidence from neuropsychological tests and event-related potentials [J]. J Headache Pain 18(1):54
30. Lo Buono V, Bonanno L, Corallo F et al (2017) Functional connectivity and cognitive impairment in migraine with and without aura [J]. J Headache Pain 18(1):72
31. Ferreira KS, Teixeira CT, Cáfora C et al (2018) Chronic migraine patients show cognitive impairment in an extended neuropsychological assessment [J]. Arq Neuropsiquiatr 76(9):582–587
32. Tun A, Tekeşin AK, Güngen BD et al (2018) Cognitive performance in young and middle-aged adults with migraine: investigating the correlation with white matter hyperintensities and psychological symptoms [J]. Neurol Neurochir Pol 52(4):470–476
33. Baschi R, Monastero R, Cosentino G et al (2019) Visuospatial learning is fostered in migraine: evidence by a neuropsychological study [J]. Neurol Sci 40(11):2343–2348
34. Karami A, Khodarahimi S, Mazaheri M (2019) Cognitive and perceptual functions in patients with occipital lobe epilepsy, patients with migraine, and healthy controls [J]. Epilepsy Behav 97:265–268
35. Martins IP, Maruta C, Alves PN et al (2020) Cognitive aging in migraine sufferers is associated with more subjective complaints but similar age-related decline: a 5-year longitudinal study [J]. J Headache Pain 21(1):31
36. Tysa SL, Manfreda J, Strain LA et al (2001) Risk factors for Alzheimer’s disease: a population-based, longitudinal study in Manitoba, Canada [J]. J Epidemiol 30(3):590–597
37. Chung CS, Lin CL, Lin MC et al (2013) Migraine and risk of dementia: a nationwide retrospective cohort study [J]. Neuroepidemiology 41(3–4):139–145
38. (2013) Abstracts of the 2013 International Headache Congress, 27–30 June 2013, Boston, MA, USA [J]. Cephalalgia : an international journal of headache 33(8 Suppl):1–309
39. Hagen K, Stordal E, Linde M et al (2014) Headache as a risk factor for dementia: a prospective population-based study [J]. Cephalalgia 34(5):327–335
40. Tseng NS, Chung CH, Lin FH et al (2017) Headaches and risk of dementia [J]. Am J Med Sci 353(3):197–206
41. Kostev K, Bohlken J, Jacob L (2019) Association between migraine headaches and dementia in more than 7,400 patients followed in general practices in the United Kingdom [J]. J Alzheimers Dis 71(1):353–360
42. Morton RE, John P, Tysa SL (2019) Migraine and the risk of all cause dementia, Alzheimer’s disease, and vascular dementia: a prospective cohort study in community-dwelling older adults [J]. Int J Geriatr Psychiatry 34(11):1667-1676
43. Liang Y, Gao Y, Wang R et al (2022) Migraine, cognitive decline, and dementia in older adults: a population-based study [J]. J Alzheimers Dis 88(1):263-271
44. Zhang J, Su J, Wang M et al (2016) Increased default mode network connectivity and increased regional homogeneity in migraineurs without aura [J]. J Headache Pain 17(1):98
45. Tesitore A, Russo A, Conte F et al (2015) Abnormal connectivity within executive resting-state network in migraine with Aura [J]. Headache 55(6):794–805
46. Puledda F, Flytche D, O’daly O et al (2019) Imaging the visual network in the migraine Spectrum [J]. Front Neuro 10:1325
47. Yeshurun Y, Nguyen M, Hasson U (2021) The default mode network: where the idiosyncratic self meets the shared social world [J]. Nat Rev Neurosci 22(3):181–192
48. Damoiseaux JS, Rombouts SA, Barkhof F et al (2006) Consistent resting-state functional connectivity between right frontoparietal and visual cortex in migraine with Aura [J]. Headache 46(1):103(37):13848–13853
49. Zhao Q, Sang X, Metmer H et al (2019) Functional segregation of executive resting-state network in migraine with Aura [J]. J Headache Pain 21(1):31
50. Küchenhoff S, Sorg C, Schneider SC et al (2021) Visual processing speed is better cognition in the middle-aged and elderly: the Rotterdam study [J]. Eur J Neurol 23(10):1510–1516
51. Jiang W, Liang G-H, Li J-A et al (2022) Migraine and the risk of dementia in community-dwelling older adults Consulting in Primary Care [J]. Pain Med Pharmacol Sci 20(23):4913–4917
52. Bigal ME, Kurth T, Santangelo N et al (2010) Migraine and cardiovascular disease: a population-based study [J]. Neurology 74(8):628–635
53. Adelborg K, Sz Pligeti SK, Holland-Bill L et al (2018) Migraine and risk of cardiovascular diseases: Danish population based matched cohort study [J]. BMJ 360:k936
54. Debette S, Schilling S, Duperron MG et al (2019) Clinical significance of magnetic resonance imaging markers of vascular brain injury: a systematic review and Meta-analysis [J]. JAMA Neurol 76(1):81–94
55. Graff-Radford J, Arenaza-Urquijo EM, Knopman DS et al (2019) White matter hyperintensities: relationship to amyloid and tau burden [J]. Brain 142(8):2483–2491

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.